Literature DB >> 26089092

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

W Glenn McCluggage1, Meagan J Judge2, Blaise A Clarke3, Ben Davidson4, C Blake Gilks5, Harry Hollema6, Jonathan A Ledermann7, Xavier Matias-Guiu8, Yoshiki Mikami9, Colin J R Stewart10, Russell Vang11, Lynn Hirschowitz12.   

Abstract

A comprehensive pathological report is essential for optimal patient management, cancer staging and prognostication. In many countries, proforma reports are used but these vary in their content. The International Collaboration on Cancer Reporting (ICCR) is an alliance formed by the Royal College of Pathologists of Australasia, the Royal College of Pathologists of the United Kingdom, the College of American Pathologists, the Canadian Partnership Against Cancer and the European Society of Pathology, with the aim of developing an evidence-based reporting data set for each cancer site. This will reduce the global burden of cancer data set development and reduplication of effort by different international institutions that commission, publish and maintain standardised cancer reporting data sets. The resultant standardisation of cancer reporting will benefit not only those countries directly involved in the collaboration but also others not in a position to develop their own data sets. We describe the development of a cancer data set by the ICCR expert panel for the reporting of primary ovarian, fallopian tube and peritoneal carcinoma and present the 'required' and 'recommended' elements to be included in the report with an explanatory commentary. This data set encompasses the recent International Federation of Obstetricians and Gynaecologists staging system for these neoplasms and the updated World Health Organisation Classification of Tumours of the Female Reproductive Organs. The data set also addresses issues about site assignment of the primary tumour in high-grade serous carcinomas and proposes a scoring system for the assessment of tumour response to neoadjuvant chemotherapy. The widespread implementation of this data set will facilitate consistent and accurate data collection, comparison of epidemiological and pathological parameters between different populations, facilitate research and hopefully will result in improved patient management.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26089092     DOI: 10.1038/modpathol.2015.77

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  152 in total

1.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

2.  Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Authors:  Kala Visvanathan; Russell Vang; Patricia Shaw; Amy Gross; Robert Soslow; Vinita Parkash; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

3.  An analysis of two versus three grades for endometrial carcinoma.

Authors:  R R Taylor; J Zeller; R W Lieberman; D M O'Connor
Journal:  Gynecol Oncol       Date:  1999-07       Impact factor: 5.482

4.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

5.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

Review 6.  Recent advances in immunohistochemistry in gynaecological pathology.

Authors:  W G McCluggage
Journal:  Histopathology       Date:  2002-04       Impact factor: 5.087

Review 7.  Hereditary gynaecological malignancies: advances in screening and treatment.

Authors:  Ann K Folkins; Teri A Longacre
Journal:  Histopathology       Date:  2013-01       Impact factor: 5.087

8.  Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.

Authors:  Debra A Bell; Teri A Longacre; Jaime Prat; Elise C Kohn; Robert A Soslow; Lora H Ellenson; Anais Malpica; Mark H Stoler; Robert J Kurman
Journal:  Hum Pathol       Date:  2004-08       Impact factor: 3.466

9.  WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.

Authors:  M Al-Hussaini; A Stockman; H Foster; W G McCluggage
Journal:  Histopathology       Date:  2004-02       Impact factor: 5.087

10.  Prognostic factors in patients with stage I epithelial ovarian cancer.

Authors:  A J Dembo; M Davy; A E Stenwig; E J Berle; R S Bush; K Kjorstad
Journal:  Obstet Gynecol       Date:  1990-02       Impact factor: 7.661

View more
  35 in total

1.  Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Authors:  Laura Ardighieri; Luigi Mori; Sara Conzadori; Mattia Bugatti; Marcella Falchetti; Carla Maria Donzelli; Antonella Ravaggi; Franco E Odicino; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

2.  [The 2016 update of the S3 guideline for malignant tumours of the ovary : Role of pathology in diagnosis, therapy and clinical management of epithelial tumours].

Authors:  A Staebler; D Mayr
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 3.  [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

4.  Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Authors:  Naveena Singh; Asma Faruqi; Friedrich Kommoss; W Glenn McCluggage; Giorgia Trevisan; Janine Senz; Amy Lum; C Blake Gilks; Michael Anglesio
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

Review 5.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

6.  Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma.

Authors:  Tushar Kar; Asaranti Kar; Ipsita Dhal; Sasmita Panda; Priyadarshini Biswal; Bhagyalaxmi Nayak; Niranjan Rout; Sagarika Samantray
Journal:  J Obstet Gynaecol India       Date:  2017-06-01

7.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

Review 8.  [TNM classification of gynecologic malignancies : What remains to be done beyond 2017?]

Authors:  L-C Horn; C E Brambs; S Opitz; J Einenkel; D Mayr
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

9.  Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study.

Authors:  Aditi Bhatt; Praveen Kammar; Snita Sinukumar; Loma Parikh; Nutan Jumle; Sakina Shaikh; Sanket Mehta
Journal:  Ann Surg Oncol       Date:  2020-08-03       Impact factor: 5.344

10.  Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Authors:  Andrew Churg; Richard Attanoos; Alain C Borczuk; Lucian R Chirieac; Françoise Galateau-Sallé; Allen Gibbs; Douglas Henderson; Victor Roggli; Valerie Rusch; Meagan J Judge; John R Srigley
Journal:  Arch Pathol Lab Med       Date:  2016-03-31       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.